All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Lisocabtagene maraleucel receives positive CHMP opinion for the treatment of adult patients with R/R FL
On January 31, 2025, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who progress after ≥2 lines of systemic therapy. This announcement is based on key results from the phase II TRANSCEND FL trial (NCT04245839).1
TRANSCEND FL trial1
TRANSCEND FL is an open-label, global, multicenter, phase II, single-arm study to determine the efficacy and safety of liso-cel in adult patients with R/R indolent B-cell non-Hodgkin lymphoma, including FL, who received ≥2 prior lines of systemic therapy. Among the evaluable patients with FL1:
- The overall response rate was 97.1% (95% CI, 91.7–99.4).
- The complete response rate was 94.2% (95% CI, 87.8–97.8).
- The 18-month duration of response rate was 75.7% (95% CI, 66.0–83.0).
- Safety data from the study were consistent with the known adverse-effect profile of liso-cel, and no new safety signals were identified.
In May 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to liso-cel for the treatment of adult patients with R/R FL who have received ≥2 prior lines of systemic therapy.2
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What is your preferred therapy class when planning treatment for a patient with R/R DLBCL after 2 or more lines of systemic therapy ?
